[FGF23 related hypophosphatemic rickets:current therapy and unresolved issues]
Related Experiment Video
Updated: Mar 26, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Daisuke Harada1, Noriyuki Namba1
1Department of Pediatrics, Japan Community Health care Organization(JCHO)Osaka Hospital, Japan.
Abstract:
FGF23-related hypophosphatemic rickets is basically treated with active vitamin D and phosphorus. The treatment goals are to minimize bone deformity and improve adult height in children, and to relieve pain and decrease osteomalacia in adult. However, since they do not target the underlying molecular defect, bone deformity can worsen during growth and adult height is suboptimal restricted. Many adult patients suffer from enthesopathy leading to symptoms such as spinal cord compression and debilitating pain. At present, no treatment is effective in preventing or revenging this complication. The recently developed anti-FGF23 antibody may potentially be a more fundamental treatment.
More Related Videos
Related Concept Videos
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Chronic Kidney Disease III: Interprofessional Care
Introduction to Electrolytes
Role of Sodium
One...
Cystic Fibrosis: Management
Sinus disease and chronic...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Kidney Disease II: Clinical Manifestations

